Will Journey Medical stock go up?

According to Danelfin AI, Journey Medical has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.67%) is +1.85% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Journey Medical stock?

The Journey Medical target price is $14.4 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Journey Medical stock right now?

Journey Medical has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.67%) is +1.85% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Journey Medical stock is a good buy .

Is Journey Medical undervalued right now?

Based on analysts, the average price target upside for Journey Medical is +103.93% (1Y). According to Danelfin AI, Journey Medical has today an AI Score of 5/10 (Hold Rating).

What was the price range of Journey Medical stock over the past 12 months?

The Journey Medical stock price range over the past 12 months has been $4.39 - $9.26.

What is going on with Journey Medical stock in the last 3 months?

The Journey Medical stock performance in the last quarter has been +50.53%.

Does Journey Medical offer dividend payments?

No, Journey Medical does not currently pay dividends.

What is the current market capitalization of Journey Medical?

Journey Medical's market cap is $193.84M, as of 2026-07-02 08:00.

When is the next DERM earnings report date?

DERM will publish its next earnings report on 2026-05-13.

Journey Medical Corp (DERM) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

DERM AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+2.75%
Direction and strength of recent price movements
Earnings Quality+0.31%
Stability and reliability of reported earnings
Size & Liquidity+0.15%
Company size and trading liquidity
Sentiment+0.11%
How analysts and the market view the stock

Valuation-0.61%
How the stock is priced relative to its fundamentals
Volatility-0.57%
How much the stock price tends to fluctuate
Profitability-0.28%
Profitability and operating efficiency metrics

DERM probability advantage of beating the market (3M):

+1.85%

Technical

Journey Medical (DERM) has a Technical Score of 7/10 because, according to only technical analysis, it has a probability advantage of +4.53% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.64%) and the probability of DERM (55.17%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.64%
DERM probability advantage of beating the market (only technical, 3M)+4.53%
DERM probability of beating the market (3M)55.17%

DERM probability advantage of beating the market (only technical, 3M): +4.53%

The AI-powered technical analysis of Journey Medical (DERM) is only based on the 30 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of DERM:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+1.47%
Technical	Upgrade to Pro to unlock	+0.81%
Technical	Upgrade to Pro to unlock	+0.54%
Technical	Upgrade to Pro to unlock	+0.38%
Technical	Upgrade to Pro to unlock	-0.32%
Technical	Upgrade to Pro to unlock	+0.31%
Technical	Upgrade to Pro to unlock	-0.29%
Technical	Upgrade to Pro to unlock	-0.27%
Technical	Upgrade to Pro to unlock	+0.26%
Technical	Upgrade to Pro to unlock	-0.25%
Technical	Upgrade to Pro to unlock	-0.25%
Technical	Upgrade to Pro to unlock	+0.24%
Technical	Upgrade to Pro to unlock	-0.24%
Technical	Upgrade to Pro to unlock	+0.24%
Technical	Upgrade to Pro to unlock	+0.24%

Rest of Alpha Signals: +1.66%

DERM probability advantage of beating the market (only technical, 3M)Total:+4.53%
DERM Technical Score

Significant changes Vs previous day

DERM Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$7.06
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

DERM Proven Hold Signal & Price Forecast

This is the price chart for DERM from January 2, 2026 until today. The chart indicates, in yellow, the 108 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

DERM Average Past Performance & Win Rate

Three months after its 592 Hold signals since July 2026, DERM had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

592 Past DERM Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+37.82%
Average Alpha				+27.15%
Win Rate (% Positive Perf.)				60.93%
% Positive Alpha				57.07%

DERM Frequently Asked Questions

Will Journey Medical stock go up?
According to Danelfin AI, Journey Medical has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.67%) is +1.85% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Journey Medical stock?
Is it a good time to buy, sell, or hold Journey Medical stock right now?
Is Journey Medical undervalued right now?
What was the price range of Journey Medical stock over the past 12 months?
What is going on with Journey Medical stock in the last 3 months?
Does Journey Medical offer dividend payments?
What is the current market capitalization of Journey Medical?
When is the next DERM earnings report date?

Journey Medical Corp Company Profile

Journey Medical Corporation prioritizes the research, development, and market launch of pharmaceutical solutions designed specifically for dermatological concerns across the United States. The corporation's product portfolio includes Qbrexza, a medicated cloth pad designed to manage primary axillary hyperhidrosis; Accutane, an orally-administered isotretinoin-based medication formulated to address severe treatment-resistant acne; Targadox, an oral variant of doxycycline created as an adjunctive therapy for serious acne conditions; Zilxi which is a topical application of minocycline intended for treating inflammatory lesions; Ximino, taken orally to handle moderate to severe acne manifestations; and Exelderm cream and solution for topical usage.

Moreover, the corporation commercializes doxycycline hyclate tablets, minocycline hydrochloride capsules, in addition to sulconazole nitrate cream and solution. Previously acknowledged as Coronado Dermatology Inc., the company rebranded itself as Journey Medical Corporation is now associated with the latter name. Journey Medical Corporation was incorporated back in 2014 and set its headquarters in Scottsdale, Arizona. It is currently structured as a branch of Fortress Biotech Incorporated.

Sector:
Country:United States
Industry:
Address:9237 E Via De Ventura Blvd., Suite 105, Suite 105, Scottsdale
Employees:58
Website:journeymedicalcorp.com

Pros

Specialized market focus in dermatology

Intellectual property protection for approved therapies

Established commercial infrastructure for dermatology

Revenue stream from chronic dermatological conditions

Patient adherence creating high switching costs

Cons

High research and development expenditure requirements

Regulatory approval uncertainty for pipeline assets

Exposure to patent expiration and generic competition

Payer reimbursement pressure on drug pricing

Supply chain dependency for active pharmaceutical ingredients

Company	AI Score	Compare
MDCXMedicus Pharma Ltd
FBIOFortress Biotech Inc
DRMADermata Therapeutics Inc
BDRXBiodexa Pharmaceuticals PLC
OCULOcular Therapeutix Inc

Company	AI Score	Compare
MDCXMedicus Pharma Ltd
FBIOFortress Biotech Inc
DRMADermata Therapeutics Inc
BDRXBiodexa Pharmaceuticals PLC
OCULOcular Therapeutix Inc

DERM Stock AI Analysis